Csenge Advisory Group Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Csenge Advisory Group increased its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% during the second quarter, Holdings Channel.com reports. The firm owned 46,900 shares of the biopharmaceutical company’s stock after acquiring an additional 1,305 shares during the quarter. Csenge Advisory Group’s holdings in Pfizer were worth $1,312,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Olistico Wealth LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at about $25,000. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new position in shares of Pfizer in the fourth quarter worth approximately $37,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 0.3 %

Shares of NYSE PFE traded down $0.10 during trading on Thursday, reaching $28.76. The company had a trading volume of 32,059,725 shares, compared to its average volume of 39,918,582. The business’s 50-day moving average is $28.79 and its 200 day moving average is $27.86. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a market cap of $162.94 billion, a PE ratio of -478.83, a P/E/G ratio of 1.07 and a beta of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.19.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.31%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.84%. Pfizer’s payout ratio is -2,800.00%.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.